secwatch.observer — SEC 8-K summary
======================================

Issuer:     Design Therapeutics, Inc. (DSGN)
CIK:        0001807120
Form:       8-K
Filed at:   2026-05-18T11:15:07+00:00
Accession:  0001193125-26-227875
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Design Therapeutics reports positive Phase 1/2 data for DT-216P2 in Friedreich ataxia
--------------------------------------------------------------------------------

- After 4 weeks at 1 mpk, mFARS improved 6.4 points, Upright Stability Score 2.7 points, fatigue >5 points (PROMIS).
- Whole blood FXN mRNA increased 65% (p<0.001); muscle FXN mRNA up 42% (p=0.015); FXN protein increased 22-27%.
- DT-216P2 well-tolerated; no serious adverse events or discontinuations; mild-moderate transient ALT elevations in 3 patients.
- Company plans to pursue registrational path; update expected in Q4 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1807120/000119312526227875/0001193125-26-227875-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1807120/000119312526227875/d154773d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-227875

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer